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Summary
Peptide YY (PYY) is a postprandially released gut hormone. Peripheral administration of one form of the peptide PYY3-36
produces a short-term reduction in food intake in rodents. Initial reports suggested that effects of PYY3–36 on food intake
are mediated by increasing the anorexigenic drive from melanocortin neurons in the hypothalamic arcuate nucleus. How-
ever, more recent data have demonstrated that the anorexigenic activity of PYY3–36 is not dependent on melanocortin
ligands or their receptors in the CNS. We demonstrate here that the anorexigenic actions of PYY3–36 are also not depen-
dent on the vagus nerve, a common pathway of satiety signaling. Peripherally administered PYY3–36 activates neurons in
the area postrema and nucleus tractus solitarius, brainstem areas known to mediate effects of certain aversive stimuli.
Furthermore, peripheral administration of PYY3–36 causes conditioned taste aversion in mice. Thus, inhibition of food
intake by PYY3–36 may result in part from induction of an aversive response.Introduction
Key sites in the brain, like the arcuate nucleus (ARC) of the
hypothalamus and the nucleus tractus solitarius (NTS) of the
brainstem, maintain energy homeostasis by integrating periph-
eral signals of energy availability with energy intake and expen-
diture. The energy normally used for expenditure comes in two
forms: either as stored energy, in the form of glycogen and fat
deposits, or as newly ingested energy from a meal. Leptin, an
adipostatic signal, is known to relay information about the
long-term energy reserves in adipocytes. Gut peptides, like
cholecystokinin (CCK) and ghrelin, along with vagal afferent
signals, relay satiety and hunger signals to regulate meal size
and frequency.
CCK is the archetypal satiety peptide released postprandially
from the gut. The proposed mechanism by which CCK causes
satiety, under physiological conditions, is through activation of
CCK-A receptors on the vagus (Ritter and Ladenheim, 1985).
After activation, vagal afferents transmit the signal to the NTS,
activating a broad array of NTS neurons to stimulate meal ter-
mination. However, at high concentrations, peripherally admin-
istered CCK causes vagally mediated taste aversion (Ervin et
al., 1995; Verbalis et al., 1986) and activates neurons in the
area postrema (AP) (Luckman, 1992), a circumventricular organ
outside the blood-brain barrier (BBB) implicated in mediating
the response to aversive stimuli (Miller and Leslie, 1994).
PYY3–36 is yet another secreted gut peptide, first reported by
two laboratories, to produce a short-lived inhibition of food in-
take in rats and mice and to reduce the rate of weight gain in
rats (Batterham et al., 2002). This peptide has achieved addi-
tional attention due to the observation that continuous intrave-
nous infusion of PYY3–36 reduced 24 hr food intake and hunger
scores in a small number of lean and obese human subjects,
suggesting a potential clinical utility of the peptide in the treat-
ment of obesity (Batterham et al., 2002; Batterham et al.,CELL METABOLISM : MARCH 2005 · VOL. 1 · COPYRIGHT © 2005 ELSE2003). However, following the initial report, 12 laboratories, in
a single publication, reported a lack of anorexigenic activity for
PYY3–36 in rats and mice and also did not find a reduction in
the rate of weight gain (Tschop et al., 2004). Since that time,
five additional laboratories have repeated the original finding of
acute inhibition of feeding by peripheral administration of
PYY3–36 in rats or mice (Adams et al., 2004; Challis et al., 2004;
Chelikani et al., 2005; Cox and Randich, 2004; Pittner et al.,
2004), and one laboratory has demonstrated inhibition of feed-
ing in rhesus monkeys (Moran et al., 2005). Two additional ob-
servations may shed light on this discrepancy. First, careful ac-
climatization of mice appears to be required to see the effects
of PYY3–36 on acute food intake (Halatchev et al., 2004), sug-
gesting that the effect of the peptide may be sensitive to a
variety of stressors. Secondly, intravenous infusion of PYY3–36
in rats for 3 hr, meant to mimic the postprandial rise in the
peptide, potently inhibited food intake, while a 15 min dosing
was much less efficacious, suggesting that the bolus intraperi-
toneal (i.p.) administration of the peptide used in most studies
may be a much less effective route of administration (Chelikani
et al., 2005). Indeed, 11 of the 12 studies in the negative report
utilized i.p. administration; the single study using subcutane-
ous infusion showed a statistically significant inhibition of food
intake for 3 days (Tschop et al., 2004). One study using subcu-
taneous infusion of the peptide has now reproduced the initial
finding of a reduction of cumulative food intake and the rate of
weight gain in a variety of normal and obese murine models
(Pittner et al., 2004).
PYY1–36 is secreted from L cells in the ileum and colon in
response to ingested fatty acids and other nutrients (Adrian et
al., 1985; Bottcher et al., 1986; Bottcher et al., 1993). In the
circulation, PYY1–36 is cleaved by dipeptidyl peptidase-IV
(DPP-IV) to produce PYY3–36 (Grandt et al., 1994). The PP fold,
a common tertiary structure shared between PYY3–36 and all
other NPY family peptides, confers its specificity for the NPYVIER INC. DOI 10.1016/j.cmet.2005.02.003 159
A R T I C L EFigure 1. Lepob/Lepob and Leprdb/Leprdb mice re-
spond equivalently to peripherally administered
PYY3–36 in a nocturnal feeding paradigm
A) Nocturnal feeding response of Lepob/Lepob mice
to saline or a PYY3–36 dose of 5 g/100 g at 2, 4,
and 6 hr post injection (n = 6, each group).
B) Nocturnal feeding response of Leprdb/Leprdb
mice to saline or a PYY3–36 dose of 5 g/100 g at
2, 4, and 6 hr post injection (n = 5, each group). Data
is expressed as mean ± SEM, statistics by repeated
measures two-way ANOVA followed by a Student’s
(two-tailed) t test, *p < 0.05, **p < 0.01, ***p < 0.001.receptors 1–5 (Y1–Y5) (for review, see Keire et al. [2002]).
PYY3–36 has high-affinity binding restricted to the Y2 (Ki =
0.03–0.3 nM) and Y5 receptors (Keire et al., 2002).
Initially, PYY3–36 was postulated to exert its anorexigenic ef-
fects through activation of ARC POMC neurons (Batterham et
al., 2002). Using an in vitro slice preparation, PYY3–36 was ob-
served to reduce inhibitory postsynaptic potentials onto POMC
neurons and increase the basal firing rate of these neurons,
presumably via Y2 receptor on NPY neurons (Batterham et al.,
2002). In this model, PYY3–36 is proposed to have direct ano-
rexigenic actions in the ARC, gaining access either through the
median eminence, a circumventricular organ, or through the
blood-brain barrier. Furthermore, peripheral administration of
PYY3–36 increased c-Fos immunoreactivity (IR), a marker of
neuronal activation, in w12% of POMC neurons in the ARC,
compared to saline-treated mice (Batterham et al., 2002; Ha-
latchev et al., 2004) .
However, a number of recent reports have shown that this
model may need to be reconsidered. Unexpectedly, in a noc-
turnal feeding and/or fast-induced refeeding paradigm, MC4-R
knockout (MC4-R−/−) (Halatchev et al., 2004), Agouti (Martin et
al., 2004), and POMC knockout mice (POMC−/−) (Challis et al.,
2004) showed a reduction of food intake comparable to wild-
type (wt) sex- and age-matched controls after peripheral ad-
ministration of PYY3–36. These studies demonstrated that
melanocortin signaling is not necessary for the anorexigenic
effects of PYY3–36, and an alternative mechanism should be
considered.
In this study, we sought to identify alternative mechanisms
of action for PYY3–36. We first tested if, like CCK, PYY3–36 re-
quires the vagus nerve for its actions or requires intact leptin
signaling. Using c-Fos as a marker of neuronal activation, we
also systematically examined brain regions activated by in-
creasing peripheral doses of PYY3–36 in order to identify other
potential sites of action. Finally, we examined the ability of the
peptide, at doses that reliably and reproducibly inhibit food in-
take, to induce conditioned taste aversion.
Results
Intact leptin signaling is not essential
for the actions of PYY3–36
Signals relaying information about long-term energy stores and
immediately available energy are integrated at key sites in the160brain (for review, see Wang et al. [2000]) or Ellacott and Cone
[2004]). It has been shown previously, for example, that leptin
and CCK can act synergistically to inhibit food intake (Barra-
china et al., 1997; Emond et al., 1999; Matson et al., 1997).
Furthermore, rodents with deficient leptin signaling are hypo-
sensitive to peripherally administered CCK (McLaughlin and
Baile, 1980; Niederau et al., 1997). To test the hypothesis that
the anorexigenic effects of PYY3–36 might be abolished in the
absence of leptin signaling, we examined the ability of PYY3–36
to reduce food intake in Lepob/Lepob and Leprdb/Leprdb mice,
two models of obesity caused by a disruption in the ligand
or the receptor, respectively, required for leptin signaling. In a
nocturnal free-feeding paradigm, PYY3–36 (5 g/100 g) was in-
jected i.p. in Lepob/Lepob and/or Leprdb/Leprdb mice right be-
fore lights out (1900 hr), and their food intake was measured
every 2 hr for 6 hr. PYY3–36 transiently but significantly reduced
food intake in Lepob/Lepob mice in the first 4 hr (Figure 1A).
Lepob/Lepob mice treated with the peptide ate 47% ± 11% less
food in the first 2 hr and 39% ± 15% less food in 4 hr com-
pared to saline-treated controls (Figure 1A), levels nearly iden-
tical to the reduction seen in wt mice by the same dose of
PYY3–36 (Figure 2B). By 6 hr, there was no difference in food
consumption between saline and PYY3–36-treated Lepob/Lepob
mice (Figure 1A). Likewise, i.p. PYY3–36 significantly reduced
food intake in Leprdb/Leprdb mice for the same duration and to
the same degree (Figure 1B). The peptide treated group of
Leprdb/Leprdb mice ate 46% ± 9% less food at 2 hr and
38% ± 15% less at 4 hr compared to saline-treated controls
(Figure 1B), also a nearly identical reduction in food intake to
wt mice by the same dose of PYY3–36 (Figure 2B). As in Lepob/
Lepob mice, the effect of PYY3–36 in Leprdb/Leprdb mice was
transient; no difference in food consumption was observed at
6 hr (Figure 1B).
The vagus nerve is not essential for the inhibition
of feeding by PYY3–36
Gut peptides implicated in the acute regulation of hunger and
satiety, such as ghrelin and CCK, have been shown to require
the vagus nerve for their actions (Date et al., 2002; Smith et
al., 1985). We postulated that PYY3–36, a postprandially re-
leased gut peptide, may also require the vagus nerve to medi-
ate its anorexic activity. To test this hypothesis, we injected
PYY or saline i.p. in wt mice with both vagus nerves surgi-3–36
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PYY3-36 induces conditioned taste aversionFigure 2. Intact vagus nerves are not essential for
the actions of peripherally administered PYY3–36 in
a nocturnal feeding paradigm
A) Nocturnal feeding responses of Sham and BSDV
mice to i.p. CCK-8 dose of 10 g/kg at 2 hr post
injection (Sham saline and CCK-8, n = 10; BSDV
saline and CCK-8, n = 6).
B) Nocturnal feeding responses of Sham and BSDV
mice to i.p. PYY3–36 dose of 5 g/100g at 2, 4, 6,
and 8 hr post injection (Sham saline and CCK-8, n =
10; BSDV saline and CCK-8, n = 6). Data is ex-
pressed as mean ± SEM, statistics by Student’s
(two-tailed) t test for (A) and repeated measures
two-way ANOVA followed by one-way ANOVA with
Bonferroni’s tests posthoc for each time point in (B),
*p < 0.05, **p < 0.01, ***p < 0.001.cally transected below the level of the diaphragm (BSDV mice)
and compared their responses to animals whose vagus nerves
were surgically isolated and separated but not transected
(Sham mice). We chose a nocturnal free-feeding paradigm to
assay the effects of PYY3–36 on food intake because we found
it eliminated the reduction of food intake in vagotomized mice
that occurs due to stress in a fast-induced refeeding paradigm.
Using CCK-8, we demonstrated that both vagus nerves were
completely transected in BSDV mice and that Sham mice
did not have their vagus nerves accidentally cut (Figure 2A).
CCK-8 (10 g/kg i.p.) significantly reduced 2 hr nocturnal food
intake in the Sham surgical group but not in the BSDV group
(Figure 2A).
We also tested the ability of PYY3-36 (5 g/100 g) injected i.p.
immediately before lights out (1900 hr) to reduce food intake in
Sham and BSDV mice by measuring cumulative food intake
every 2 hr for 8 hr. PYY3–36 reduced food intake to the same
extent, 54% ± 7% in Sham and 46% ± 13% in BSDV mice in
the first 2 hr, as compared to saline-matched controls for each
surgical group (Figure 2B). However, PYY3–36 showed a signif-
icantly different effect across time with different surgi-
cal treatments (Sham versus BSDV), as assayed by a repeated
measures two-way ANOVA. In the Sham group, at 4 hr,
PYY3–36 significantly reduced food intake by 25% ± 10%, and
only a trend toward reduction of food intake, without signifi-
cance, was observed by 6 hr (Figure 2B). In contrast, the BSDV
group responded to PYY3–36 for an extended period of time,
such that even by 6 hr, PYY3–36 treated animals ate w30%
less than saline-treated BSDV and PYY3–36-treated Sham mice
(Figure 2B). In fact, at 8 hr post injection, a significant reduction
of food intake was measured in the PYY3–36-treated BSDV
mice as compared to saline-treated Sham controls (Figure 2B),
suggesting that BSDV mice actually exhibit prolonged sensitiv-
ity to the anorexigenic actions of a single bolus dose of
PYY3–36.
Dose-dependent activation of AP and intermediate
NTS neurons with nocturnal peripheral
administration of PYY3–36
In order to begin to address the mechanisms by which PYY3–36
inhibits food intake, it was important to characterize the mini-CELL METABOLISM : MARCH 2005mum dose of peripheral PYY3–36 required to inhibit food intake
reliably and reproducibly. We previously showed that PYY3–36
dose-dependently and transiently reduces food intake at high
doses (3 and 10 g/100 g) both in fasted and in nocturnal free-
feeding paradigms in acclimated mice (Halatchev et al., 2004).
However, at the lowest dose, 0.3 g/100 g, PYY3–36 neither
reliably nor significantly reduced food intake at any time point
in either feeding paradigm. Here, using a 16 hr fast-induced
refeeding paradigm, acclimated wt mice were injected i.p. with
increasing doses of PYY3–36 (0.3, 1.5, and 5 g/100 g), and
their cumulative food intake was measured hourly for 4 hr.
PYY3–36 dose-dependently reduced food intake for the dura-
tion of the experiment (Figure 3A). As shown previously, al-
though a trend for reduction in food intake at 0.3 g/100 g of
PYY3–36 was observed, statistical significance was not reached
at that dose compared to saline treatment (Figure 3A). How-
ever, PYY3–36 significantly and reliably reduced food intake at
the 1.5 g/100 g dose (Figure 3A) at 1, 2, and 3 hr. The highest
dose of PYY3–36 (5 g/100 g) tested significantly reduced food
intake for the duration of the experiment, 4 hr (Figure 3A), as it
did in the nocturnal feeding paradigms in Sham, BSDV (Figure
2B), Lepob/Lepob (Figure 1A), and Leprdb/Leprdb mice (Figure 1B).
We next wanted to identify specific sites in the brain that are
activated by peripherally administered PYY3–36. We decided to
focus on two brainstem nuclei in particular, the AP and NTS,
both known to be involved in mediating the effects of gut-
released peptides like CCK and ghrelin (Date et al., 2002; Fan
et al., 2004). Nocturnal i.p. injection (1900 hr) of increasing
doses of PYY3–36 (0.3, 1.5, and 5 g/100 g) caused a signifi-
cant dose-dependent activation of c-Fos IR in neurons in AP
and intermediate NTS (Figures 3C, 3F, 3I, 3K, and 3L), com-
pared to saline injections (Figures 3B, 3E, 3H, 3K, and 3L). The
minimum peripheral dose of PYY3–36 to reliably and reproduc-
ibly inhibit food intake, 1.5 g/100 g (Figure 3A), was also the
minimal dose to show a 2-fold statistically significant activation
of c-Fos in the intermediate NTS, compared to a saline i.p.
injection (Figure 3K). While increasing doses of i.p. PYY3–36
consistently induced c-Fos IR in a very discrete subnucleus of
the NTS, the positive control, CCK-8 (10 g/kg), dramatically
induced widespread c-Fos expression in neurons throughout
the entire NTS and AP (Figures 3D, 3G, 3J, 3K, and 3L) to levels161
A R T I C L EFigure 3. Peripheral PYY3-36 dose-dependently inhibits food intake and activates c-Fos expression in AP and intermediate NTS neurons
A) Dose-dependent inhibition of food intake at 1, 2, 3, and 4 hr after i.p. injections of saline or PYY3–36 at doses of 0.3, 1.5, and 5 g/100 g in wt mice acclimated for
5 days (n = 5).162 CELL METABOLISM : MARCH 2005
PYY3-36 induces conditioned taste aversionmuch greater than even the highest dose of PYY3–36 (Figures
3C, 3F, 3I, 3K, and 3L).
Peripheral administration of PYY3–36 causes
conditioned taste aversion in mice
A growing number of reports and observations have failed to
identify neuronal and/or hormonal systems required for the an-
orexigenic actions of PYY3–36. However, previous reports have
demonstrated a link between PYY1–36 and emesis in dogs (Har-
ding and McDonald, 1989; Perry et al., 1994). Additionally, in
this report, we have shown that there is a dose-dependent,
statistically significant activation of c-Fos IR, after peripheral
administration of PYY3–36, in intermediate NTS and AP, nuclei
known to mediate the response to aversive stimuli (Schafe et
al., 1995). This led us to the hypothesis that peripherally admin-
istered PYY3–36 may be mediating its anorexic effects through
visceral illness. We chose a two-bottle, two-flavor conditioned
taste aversion assay (Figure 4) to test whether PYY3–36, at
doses that reliably and reproducibly reduce food intake (1.5
and 5 g/100 g), causes conditioned taste aversion in mice.
Both peripheral doses of PYY3–36 (1.5 and 5 g/100 g) signifi-
cantly reduced drinking of the flavor associated with peptide
administration (PYY3–36-paired flavor) compared to the flavor
associated with the saline treatment (saline-paired flavor) (Fig-
ure 5A). Saline-treated animals (saline pairing to both flavors)
showed no preference for either bottle (Figure 5A). Intriguingly,
the minimum peripheral dose of PYY3–36 to reliably and repro-
ducibly inhibit food intake, 1.5 g/100 g (Figure 3A), and signifi-
cantly activate c-Fos IR in intermediate NTS (Figure 3K) also
caused a significant reduction in consumption of the PYY3–36-
paired flavor, compared to the saline-paired flavor (Figure 5A).
Mice that received 1.5 g/100 g PYY3–36 drank 31% ± 17%,
and mice that received 5 g/100 g PYY3–36 drank 50% ± 15%
less of the PYY -paired versus the saline-paired flavor (Fig-3–36 food intake were proposed to be mediated through the central
B–J) c-Fos expression in AP and NTS neurons. (B) Ninety minutes after i.p. saline injection, (C) 5 g/100g PYY3–36 injection, and (D) 10 g/kg CCK-8 injection.
Peripheral PYY3–36 injection (5 g/100g) specifically induces c-Fos expression in intermediate NTS at the level of AP (F) or 4V (I), as compared to the diffuse activation
by CCK-8 (10 g/kg) at the level of AP (G) or 4V (J), and low c-Fos expression with i.p. saline-injected controls at the level of AP (E) or 4V (H).
K) Quantization of c-Fos IR in the intermediate NTS neurons after i.p. administration of saline (n = 5) or PYY3–36 at increasing concentrations (0.3 g/100 g, n = 4; 1.5
g/100 g, n = 4; and 5 g/100 g, n = 5; or CCK-8 at 10 g/kg, n = 4).
L) Quantization of c-Fos IR in the AP neurons after i.p. administration of saline (n = 5) or PYY3–36 at increasing concentrations (0.3 g/100g, n = 4; 1.5 g/100 g, n =
4; and 5 g/100 g, n = 5; or CCK-8 at 10 g/kg, n = 4). Data is expressed as mean ± SEM. Statistics by one-way ANOVA with Dunnett’s test post-hoc, *p < 0.05,
**p < 0.01, ***p < 0.001.Figure 4. Schematic timeline of the conditioned taste aversion protocol
All male age-matched mice were individually housed and received 1 hr of water or flavor in two separate bottles (equidistant from the food) daily for 13 days. Each
animal was weighed and i.p. injected daily with either saline (habituation days, days 1–7, 9–11, and 13, or saline/peptide/LiCl days, 8 and 12). On the test day, mice
received both flavors in a crossover position, and intake from each bottle was measured after 1 hr.CELL METABOLISM : MARCH 2005ure 5A) at 1 hr. The largest reduction of stimulus-paired flavor
consumption was seen in the LiCl group (positive control), in
which the difference between LiCl-paired and saline-paired
flavor consumption was 96% ± 2% (Figure 5A) at 1 hr.
To directly compare the effect of the treatment (saline versus
different peptide concentrations and LiCl) on the relative con-
sumption of the stimulus-paired flavor, we also expressed the
results in ratios, in which the amount of stimulus-paired flavor
is divided by the total volume (see Experimental Procedures)
consumed by an animal (Figure 5B). PYY3–36 dose-depen-
dently and significantly reduced the ratios, compared to saline
control (Figure 5B). Compared to the saline control ratio of
0.52 ± 0.05 (n = 17), PYY3–36 had a ratio of 0.42 ± 0.05 (ns; n =
17) at 1.5 g/100 g PYY3–36 dose and 0.33 ± 0.06 (p < 0.0115;
n = 17) at 5 g/100 g PYY3–36 dose (Figure 5B). The drastic
reduction of stimulus-paired flavor consumed by the LiCl-
treated group translated to a ratio of 0.05 ± 0.03 (p < 0.0001;
n = 9) (Figure 5B).
Discussion
Two decades after the original discovery of PYY by Tatemoto
in 1980, it was demonstrated that peripheral administration of
the Y2 receptor-preferring PYY3–36 form of the peptide reduced
food intake in mice, rats, and humans (Batterham et al., 2002).
In their study, Batterham et al. (2002) also reported that
PYY3–36 decreases the tonic inhibitory drive from NPY neurons
onto POMC neurons in the ARC by activating inhibitory Y2 au-
toreceptors on NPY neurons or terminals. Furthermore, they
demonstrated that peripheral administration of PYY3–36 caused
activation of a small percentage (w12%) of POMC neurons in
ARC, assessed by expression of c-Fos, a marker of neuronal
activation. From these observations, the effects of PYY3–36 on163
A R T I C L EFigure 5. Peripheral administration of PYY3–36 at
doses that reliably inhibit food intake causes condi-
tioned taste aversion in wt mice
A) Individual flavor consumption (saline-paired
flavor versus stimulus-paired flavor) after stimulus-
paired flavor is associated with i.p. LiCl (2% BW of
0.15 M LiCl) or PYY3–36 (1.5 and 5 g/100 g)
treatment.
B) Ratios of volume of stimulus-paired flavor con-
sumed versus total volume consumed across treat-
ment groups (saline, 1.5 and 5 g/100 g, n = 17;
LiCl, n = 9). Data is expressed as mean ± SEM, sta-
tistics by Student’s (two-tailed) t test for (A) and
one-way ANOVA with Dunnett’s test post-hoc for
(B), *p < 0.05, **p < 0.01, ***p < 0.001.melanocortin system. However, since this report, a number of
published observations have raised serious doubts about the
role of the central melanocortin system in the anorexigenic ef-
fects of peripherally administered PYY3–36. Mice lacking the
POMC gene (Challis et al., 2004) or the melanocortin-4 recep-
tors (Halatchev et al., 2004) are fully responsive to the peptide.
Likewise, lean and obese agouti mice are also fully responsive
to peripheral injection of PYY3–36 (Martin et al., 2004). Never-
theless, PYY3–36 is still considered by some to be a potentially
promising therapeutic agent, since it appears to reduce food
intake in lean and obese humans (Batterham et al., 2002; Bat-
terham et al., 2003) as well as in normal and obese mice
(Pittner et al., 2004). In two studies from the same laboratory,
human subjects were infused with the peptide intravenously
and showed 33% reduction of calories consumed in a meal.
Additional studies will be necessary to validate these observa-
tions in the human as well as to determine if there is any clinical
efficacy in the treatment of obesity. Nevertheless, elucidation of
mechanisms by which this postprandially-released gut peptide
reduces food intake remains highly relevant.
A variety of peripheral peptides that relay information about
energy availability have synergistic effects on key circuits in the
brain involved in regulation of energy intake and expenditure.
For example, leptin, the adipostatic hormone released from ad-
ipose tissue, has synergistic actions with CCK (Barrachina et
al., 1997; Emond et al., 1999; Matson et al., 1997). However,
animal models lacking the key signal relaying long-term energy
availability, like rodents lacking leptin signaling, show desensi-
tized responses to bolus injections of some satiety factors.
CCK, for example, shows a decreased ability to induce satiety
in a number of obese rodent models, like MC4R−/− mice and
obese Zucker rats (Halatchev et al., 2004; McLaughlin and
Baile, 1980; Niederau et al., 1997). In contrast, bolus peripheral
injections of PYY3–36 reduce food intake to the same amount
and time duration in MC4R−/−, (Halatchev et al., 2004), Agouti
(Martin et al., 2004), and POMC−/− mice (Challis et al., 2004) as
they do in wt mice. Therefore, we wanted to test the efficacy
of PYY3–36 to reduce food intake in mice lacking the leptin gene
Lepob/Lepob and in mice with a mutation in the long form of
the leptin receptor Leprdb/Leprdb. PYY3–36 reduced food intake,
using a nocturnal feeding paradigm, in Lepob/Lepob and
Leprdb/Leprdb mice (Figure 1). This experiment shows that in-164tact leptin signaling is not essential for the anorexigenic actions
of PYY3–36. Furthermore, the lack of any potent desensitization
to PYY3–36 in animals lacking leptin signaling argues that
PYY3–36, in contrast to CCK, may not act via a leptin-regulated
satiety pathway.
We next wanted to determine if the effects of PYY3–36 on
food reduction require an intact vagus nerves, like the gut-
derived factors CCK and ghrelin (Date et al., 2002; Smith et al.,
1985). We chose a nocturnal nonfasted feeding paradigm to
assay the effects of peripherally administered PYY3–36 on va-
gotomized mice because we and others have observed that
fasted vagotomized animals consume less food than sham-
operated controls, presumably due to stress or gastric disten-
tion (Moran et al., 1997; Reidelberger, 1992). Our previous
observation demonstrated that stress could easily mask the
anorexigenic effects of PYY3–36 (Halatchev et al., 2004).
PYY3–36 (5 g/100 g) reduced food intake to the same extent
in vagotomized mice and Sham controls (Figure 2B). However,
in contrast to Sham mice, PYY3–36 had a prolonged duration
of effect in vagotomized mice at that dose, reducing food in-
take for up to 8 hr (Figure 2B). This observation was quite strik-
ing; instead of attenuating the effects of PYY3–36 on food in-
take, total (afferent and efferent) subdiaphragmatic vagotomy,
in fact, prolonged them. This may reflect that even though an
intact vagus nerve is not required for the short-term anorexi-
genic actions of peripheral PYY3–36, unlike CCK and ghrelin,
intact vagal tone could modulate the duration of action of
PYY3–36. Moreover, it has been shown in the literature that in-
tact efferent vagal parasympathetic tone modulates basal and
food-induced release of PYY (Zhang et al., 1993), as well as
some of the ability of the peptide to modulate gastrointestinal
(GI) transit time and glandular secretion (Chen et al., 1996; Ma-
suda et al., 1994). In contrast to the results reported here, a
recent study has demonstrated blockade of PYY 3–36-mediated
inhibition of food intake in the rat by bilateral subdiaphragmatic
vagotomy (BSDV) (Koda et al., 2005). Additional work will be
required to determine if the different findings result from spe-
cies differences between rat and mouse or from methodologi-
cal differences. For example, regulation of growth hormone re-
lease by ghrelin appears to be dependent on the vagus in rats
(Date et al., 2002) but not in humans (Takeno et al., 2004).
Even though dose response curves for PYY can be found3–36
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PYY3-36 induces conditioned taste aversionin the literature showing the magnitude and duration of food
reduction by PYY3–36, the minimum dose required to produce
significant and reliable food inhibition by i.p. administration has
not been reported in mice. Here we show that the minimum
dose of PYY3–36 needed to reliably and reproducibly cause a
short-term inhibition of food in mice is 1.5 g/100 g (Figure
3A), with varying duration of action from 1 to 3 hr (data not
shown). This dose was then used in both the neuroanatomical
and behavioral tests performed in the rest of this study.
Certain sites in the brain have been implicated in mediating
the effects of gut peptides and other hormones in the regula-
tion of satiety and long-term energy homeostasis. The hypo-
thalamus has been proposed to be a primary site of action of
the long-term adipostatic factor leptin (Elias et al., 1999). In the
brainstem, the NTS is the primary site for reception of satiety
signals from the vagus, provided by both neural and hormonal
signals from the gut, such as gastric distension and CCK (Jean,
1991). Other gut-derived factors, like amylin, appear to be va-
gus independent and act directly on brainstem structures like
the AP to inhibit feeding (Lutz et al., 1995; Lutz et al., 2001;
Riediger et al., 2002). It was thus, perhaps, surprising that a
gut-released peptide, like PYY3–36, would mediate its short-
term anorexigenic effects directly via the ARC of the hypothala-
mus. Additional work will be required to determine the mecha-
nism and relevance of activation of small numbers of arcuate
POMC neurons by PYY3–36. However, in this report, we looked
at the ability of peripherally administered PYY3–36 to activate
neurons throughout the entire NTS and other brainstem nuclei
known to be part of the gut-brain axis. Specifically, we focused
on the AP, a circumventricular organ, and the NTS, two sites
known to be involved in satiety and emesis. In a previous re-
port, focusing on a different region of the NTS expressing
POMC, we did not observe activation of neurons in the NTS
by PYY3–36 (Halatchev et al., 2004). However, here, after exam-
ining the entire NTS, we observed a dose-dependent activation
of AP and NTS neurons with increasing concentrations of
PYY3–36, as assayed by c-Fos IR, a marker of neuronal activa-
tion (Figure 3). In contrast to CCK, which dramatically activated
neurons throughout the AP and NTS, PYY3–36 activated a spe-
cific subnucleus of the NTS, the intermediate nucleus of the
NTS (Figure 3). Even though both peptides, CCK and PYY3–36,
are secreted in response to fatty acids in the GI lumen and
reduce food intake by similar amounts and over similar time
courses, the strikingly different pattern of c-Fos activation in
NTS and AP likely reflects inherent differences in their mecha-
nisms of action. A functional example of this is the fact that
CCK requires MC4-R signaling for the inhibition of food intake
while PYY3–36 does not (Fan et al., 2004; Halatchev et al.,
2004).
Aversive stimuli are well established to activate specific neu-
ronal populations within AP and intermediate NTS, such as
those induced by i.p. injection of LiCl (Schafe et al., 1995). In
fact, we observed a very similar pattern of activation of c-Fos
in the same regions of the intermediate NTS, as observed im-
mediately after i.p. LiCl and/or in response to a flavor that has
been associated with an aversive stimulus (Houpt et al., 1997;
Schafe et al., 1995), such as LiCl. Furthermore, Schafe et al.
(1995) have demonstrated that the acquisition of the aversive
memory to a substance, required for conditioned taste aver-
sion, seems to be dependent on an intact forebrain-hindbrain
relay through nerve tracts above the superior colliculus (SchafeCELL METABOLISM : MARCH 2005et al., 1995). Here we show that a single bolus i.p. injection of
PYY3–36 produces c-Fos IR in the same brainstem nuclei as
LiCl and reduces food intake. Thus, it is consistent with these
findings that, like LiCl, PYY3–36 may, at least in part, reduce
food intake by causing a short-lived aversive response. Addi-
tional data will be required, however, to determine if PYY3–36
treatment activates the same subgroup of intermediate NTS
neurons as other aversive substances like LiCl.
A number of gut-released peptides have been shown to me-
diate part of their effects on food intake through induction of
an aversive response. At high doses, CCK causes taste aver-
sion and activates neurons in AP and NTS (Deutsch and Hardy,
1977; Ervin et al., 1995). However, unlike other well-charac-
terized substances that cause an aversive response, like LiCl,
the association produced by high doses of peripheral CCK is
dependent on the vagus nerve (Verbalis et al., 1986). Here we
wanted to examine whether the dose-dependent inhibition of
food intake and c-Fos activation by PYY3–36, in the AP and
intermediate NTS, might be due to the production of a short-
term aversive response in mice. At doses that reliably and
reproducibly inhibit short-term food intake, PYY3–36 caused
conditioned taste aversion to a flavor paired with PYY3–36 treat-
ment (Figure 5). These data raise the possibility that the pri-
mary mechanism by which PYY3–36 inhibits food intake in mice
is through a short-term aversive response.
Experimental Procedures
Animals
Transgenic mice (C57BL/6J background) with enhanced green fluorescent
protein under the control of the POMC promoter (EGFP-POMC) were de-
rived from animals described previously (Cowley et al., 2001). All transgenic
animals were raised in group housing with their siblings and maintained at
23°C ± 1°C on a 12 hr light, 12 hr dark cycle (0700–1900 hr light). Mice
were allowed ad libitum access to standard chow pellets (Purina Laboratory
Rodent Diet 5001, Ralston Purina Co., St. Louis, MO;w4.5% fat by weight).
Leprdb/Leprdb and wt experimental animals of the C57BL/6J strain were
purchased to be age, sex, and weight matched (The Jackson Laboratory,
Bar Harbor, ME). Lepob/Lepob mice, male and female, were purchased from
the same source to be age and weight matched. BSDV male mice (C57BL/
6J strain) were purchased with both the anterior and posterior trunks of the
vagus nerves cut below the level of the diaphragm (Charles River Laborato-
ries, Wilmington, MA). To create Sham-operated animals, C57BL/6J mice
from the same source underwent a comparable surgery without transection
of the vagus nerves. Upon arrival, Lepob/Lepob, Leprdb/Leprdb, BSDV,
Sham, and wt mice were allowed to acclimate for 1 week under the condi-
tions stated above. All studies were conducted according to the NIH Guide
for the Care and Use of Laboratory Animals and were approved by the
animal care and use committee of Oregon Health and Science University.
Source of reagents/peptides
All experiments were performed with human PYY3–36 (Bachem, Torrance,
CA; lot 0562660), CCK-8 (Sigma-Aldrich, St. Louis, MO; lot 062K11181),
and LiCl (Sigma-Aldrich, St. Louis, MO; lot 50K0198). Peptides were certi-
fied by the manufacturer and came with HPLC data showing a single peak
with the correct molecular weight from mass spectrogram and a purity
grater than 97%. Peptides were dissolved in sterile isotonic saline and
injected in a total volume of 500 l/injection. Fresh human PYY3–36 and
CCK-8 dilutions were prepared on the day of the injection from frozen stock
solutions. LiCl was dissolved in sterile millipore-filtered water (0.66 g in 100
ml of water).
Feeding protocols
16 hr fast refeeding in acclimated wt mice
Age-matched wt male mice (8 weeks) were used for the feeding study as
described previously (Halatchev et al., 2004). In short, animals were individ-165
A R T I C L Eually housed for a week. During the second week, animals were acclimated
to the procedure by i.p. saline injections daily, with food in a petri dish and
mock food measurements every hour for 4 hr. Mice were fasted for 16 hr
the night before the experiment (1900–1100 hr). Animals were injected with
either saline or PYY3–36 i.p. at a dose of 0.3, 1.5, and 5 g/100 g, and
cumulative food intake was measured hourly for 4 hr after injections by
placing two pellets of chow in petri dishes on the floor of the cage. To
minimize error attributable to loss of food particles or bedding in petri
dishes, petri dishes and bedding were screened.
Nighttime feeding protocol in acclimated Lepob/Lepob,
Leprdb/Leprdb mice
Age-matched Lepob/Lepob (8- to 9-week-old, half male and half female) and
Leprdb/Leprdb (10-week-old female mice) were used for the nocturnal study.
As described previously (Halatchev et al., 2004), mice were individually
housed for a week. In the following week, mice were acclimated to the
procedure by injecting 500 l sterile isotonic saline i.p. immediately before
lights out (1900 hr). Two pellets of food were then placed in a petri dish and
weighed every 2 hr for 6 hr under a red light. Animals were acclimated to
the procedure until their food intake stabilized for at least 4 consecutive
days. On the 2 experimental days, separated by 48 hr of rest, animals were
injected i.p. in a crossover manner with either saline or 5 g/100 g PYY3–36
and their food intake measured every 2 hr for 6 hr. On nonexperimental
days, animals were injected i.p. with saline and food measured to establish
any deviations from baseline. Measurement error was minimized by careful
screening for food particles under red light.
Nighttime feeding protocol in acclimated Sham and BSDV mice
Age-matched Sham and BSDV male mice (8 weeks) were used for the noc-
turnal vagotomy feeding experiment. Mice underwent surgery a week be-
fore arrival and were allowed to recover their body weight and food intake
to presurgical levels for a week in group housing. Mice were individually
housed for a week, and their body weight was monitored and compared
across surgical groups and to age-matched sex-matched nonsurgical mice.
Only mice that recovered completely from surgery were used for the experi-
ment. Sham and BSDV mice were injected with 500 l of sterile isotonic
saline i.p. immediately before lights out (1900 hr), and two preweighed pel-
lets of Purina chow in petri dishes were measured every 2 hr for 8 hr using
red light. Acclimatization to the procedure was established by stabilization
of food intake over 4 consecutive days. On experimental days, sham and
BSDV mice were injected i.p. in a crossover manner with either saline or 5
g/100 g PYY3–36 and their food intake measured every 2 hr for 8 hr.
CCK-8, a peptide demonstrated to require the vagus nerve to mediate its
effects (Ritter and Ladenheim, 1985), was used to confirm that the BSDV
mice were vagotomized and that the Sham-vagotomized animals were not.
Animals received 2 days of isotonic saline injections i.p. after PYY3–36 ad-
ministration to confirm that baseline food consumption was not altered due
to experimental manipulations. On the third and fifth days, animals were
injected i.p. in a crossover manner with either saline or CCK-8 (10 g/kg)
and their food intake measured at 2 hr. Each animal was used as its own
control to determine if its vagus nerves were cut. Only Sham animals that
responded to CCK-8 by reducing their food intake and only BSDV mice that
did not show a reduction of food intake with CCK-8 were used for analysis
of the effect of vagotomy on the actions of PYY3–36. For consistency, each
individual animal’s response to CCK-8 was tested several times.
c-Fos immunohistochemistry
POMC-EGFP mice (23–27 g) were handled and injected with 250 l sterile
saline i.p. at 1900 hr for 5 days prior to the experiment to minimize back-
ground c-Fos immunoreactivity caused by stress. During the acclimatization
period, food was withdrawn from animals 2 hr prior to injections (for 3.5 hr)
to minimize neuronal activation due to feeding (Fan et al., 2004). Animals
received an i.p. injection of PYY3–36 (0.3, 1.5, and 5 g/100 g), CCK-8 (10
g/kg), or sterile saline 90 min (at lights out, 1900 hr) before being deeply
anaesthetized and underwent transcardial perfusion with 0.9% saline fol-
lowed by 4% paraformaldehyde in 0.01 M phosphate-buffered saline (PBS).
Sections from perfused brains (25 M) were cut and stored free-floating in
0.01 M PBS containing 0.03% sodium azide. The sections were incubated
for 1 hr at room temperature in blocking reagent (5% normal donkey serum
in 0.01 M PBS + 0.3% Triton X-100). After the initial blocking step, the
sections were incubated in rabbit anti-c-Fos (Ab-5), human (rabbit) poly-
clonal antibody (Oncogene Research Products, La Jolla, CA; Lot D21570)
and diluted 1:80,000 in blocking reagent for 24 hr at 4°C, followed by incu-166bation in 1:500 donkey anti-rabbit Alexa 594 (Molecular Probes Inc., Eu-
gene, OR) for 1 hr at room temperature. Between each stage, the sections
were washed thoroughly with 0.01 M PBS. At the end of the incubations,
the sections were mounted onto gelatin-coated slides, coverslipped using
gel-based fluorescence mounting media (Biomeda Corp., Foster City, CA),
and viewed under a fluorescence microscope (Axioplan 2; Zeiss Inc.,
Thornwood, NY). The number of c-Fos immunoreactive cells was counted
in sections representing certain nuclei.
Conditioned taste aversion
Age-matched (7-week-old) male wt (C57BL/6J) mice were individually
housed for 1 week with ad libitum access to food and water. After 1 week
of acclimatization to single housing, water was withdrawn right before lights
out (day 0). To acclimate mice to the i.p. injections, weighing, and timing of
water presentation, animals were presented with two water bottles (equidis-
tant from the food, and the original water bottle presented during the first
week of individual housing) at the same time (1000 hr–1100 hr) for 1 hr for
5 consecutive days (day 1–day 5). At the end of the hour, water bottles and
mice were weighed, and each animal was injected i.p. with a volume of
sterile isotonic saline, equal to 2% of its body weight (BW). Individual water
consumption from each bottle was measured for each mouse every day to
ensure mice knew that they had a choice between two bottles and drank
equally from both. On day 6, each mouse was given 1 hr access to a novel
flavor (either 0.15% saccharin with 0.05% cherry Kool-Aid or 0.15% sac-
charin with 0.05% grape Kool-Aid) instead of water in both bottles. Immedi-
ately following the 1 hr access to a novel flavor, each mouse was weighed
and received i.p. injection of 2% BW sterile isotonic saline. On the following
day (day 7), mice were given access to water for 1 hr, weighed, and injected
i.p. with 2% BW saline. On the second Kool-Aid day (day 8), each mouse
received a novel access to the other flavor (mice that received cherry on
day 6 received grape on day 8, and mice that received grape on day 6
received cherry on day 8) in both bottles, and, immediately following 1 hr
access to the second novel flavor, each mouse was weighed and injected
i.p. with either 2% BW of saline, 0.15M LiCl, or PYY3–36 at doses of 1.5 or
5 g/100 g. Animals received another day with 1 hr water access (day 9)
followed by weighing and 2% BW i.p. saline injection. On the third day of
Kool-Aid presentation (day 10), mice were allowed access to 1 hr of original
Kool-Aid flavor in both bottles (Kool-Aid flavor from day 6) immediately fol-
lowed by weighing and 2% BW i.p. saline injection for all animals. After a
day with 1 hr water access, weighing, and 2% BW i.p. saline injections (day
11), mice received a fourth day of Kool-Aid access to second flavor (same
as day 8) for 1 hr in both bottles followed by weighing and i.p. injection with
either 2% BW of saline, 0.15 M LiCl, or PYY3–36 at doses of 1.5 or 5 g/
100 g (day 12). Animals were allowed to recover for 48 hr by another day
of 1 hr access to water, weighing, and 2% BW i.p. saline injections (day
13). On test day, each mouse was presented with both Kool-Aid flavors in
random fashion, alternating bottle positions (e.g., left bottle grape versus
right bottle grape), simultaneously, and the respective individual bottle/
flavor consumption was measured for 1 hr. See Figure 4 for schematic rep-
resentation of the conditioned taste aversion (CTA) protocol.
The CTA data was represented as raw data (Figure 5A) of the volume
consumption by each animal (for the saline group, volume consumed from
either right or left bottle and, for stimulus-paired groups, volume consumed
of the saline-paired flavor [day 6 and day 10] versus PYY3–36-paired or LiCl-
paired flavor [day 8 and day 12]). Additionally, ratios of volume consumed
(Figure 5B) were calculated as (volume bottle 1 or 2 consumed)/(total
volume consumed) for saline controls or (volume of saline-paired flavor
consumed)/(volume of stimulus-paired flavor consumed + volume of saline-
paired flavor consumed) for experimental treatments. Even though indi-
vidual C57BL/6J mice showed some flavor preference (for either grape or
cherry), on average no preference was seen. On the test day, the saline-
treated group of mice showed a significant preference for the cherry flavor
due to two mice preferring the cherry flavor over the grape. However, when
a metaanalysis was performed, the flavor preference did not affect other
individual animals’ preference for flavor in the other treatment groups.
Statistics
Statistical analyses were performed using PRISM (GraphPad Software, Inc.,
San Diego, CA). Data is expressed as mean ± SEM. For Figure 1, a repeated
measures two-way ANOVA was used to determine the effect of time on
drug treatment followed by an unpaired Student’s (two-tailed) t test to de-
termine significance at each time point. Significance was determined usingCELL METABOLISM : MARCH 2005
PYY3-36 induces conditioned taste aversionan unpaired Student’s (two-tailed) t test Figures 2A and 5A. For Figure 2B,
a repeated measures two-way ANOVA was used to assay the effects of
time across the different treatment paradigms (surgery and drug) followed
by one-way ANOVA with Bonferroni’s tests posthoc to determine signifi-
cance across individual treatments. One-way ANOVA with Dunnett’s test
posthoc was used to determine significance across treatments in Figures 3
and 5B. Significance was taken as p < 0.05.
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